Fig. 3From: Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial a Progression-free survival of patients in the ascend group and the stable group. b Overall survival of patients in the ascend group and the stable groupBack to article page